How to buy Karyopharm Therapeutics stock - 05 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Karyopharm Therapeutics stock

Own Karyopharm Therapeutics stock in just a few minutes.


Fact checked

Karyopharm Therapeutics Inc is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Karyopharm Therapeutics employs 432 staff and has a trailing 12-month revenue of around USD$108.1 million.

How to buy shares in Karyopharm Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Karyopharm Therapeutics. Find the stock by name or ticker symbol: KPTI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Karyopharm Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Karyopharm Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Karyopharm Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Karyopharm Therapeutics share price

Use our graph to track the performance of KPTI stocks over time.

Karyopharm Therapeutics shares at a glance

Information last updated 2021-03-03.
52-week rangeUSD$13.17 - USD$28.04
50-day moving average USD$15.0999
200-day moving average USD$15.3442
Wall St. target priceUSD$30
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-3.55

Buy Karyopharm Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Karyopharm Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Karyopharm Therapeutics financials

Revenue TTM USD$108.1 million
Gross profit TTM USD$-45,433,000
Return on assets TTM -35.33%
Return on equity TTM -391.29%
Profit margin -181.59%
Book value $0.684
Market capitalisation USD$951.6 million

TTM: trailing 12 months

Shorting Karyopharm Therapeutics shares

There are currently 15.7 million Karyopharm Therapeutics shares held short by investors – that's known as Karyopharm Therapeutics's "short interest". This figure is 10.9% up from 14.2 million last month.

There are a few different ways that this level of interest in shorting Karyopharm Therapeutics shares can be evaluated.

Karyopharm Therapeutics's "short interest ratio" (SIR)

Karyopharm Therapeutics's "short interest ratio" (SIR) is the quantity of Karyopharm Therapeutics shares currently shorted divided by the average quantity of Karyopharm Therapeutics shares traded daily (recently around 3.3 million). Karyopharm Therapeutics's SIR currently stands at 4.74. In other words for every 100,000 Karyopharm Therapeutics shares traded daily on the market, roughly 4740 shares are currently held short.

However Karyopharm Therapeutics's short interest can also be evaluated against the total number of Karyopharm Therapeutics shares, or, against the total number of tradable Karyopharm Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karyopharm Therapeutics's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Karyopharm Therapeutics shares in existence, roughly 210 shares are currently held short) or 0.2241% of the tradable shares (for every 100,000 tradable Karyopharm Therapeutics shares, roughly 224 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Karyopharm Therapeutics.

Find out more about how you can short Karyopharm Therapeutics stock.

Karyopharm Therapeutics share dividends

We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.

Karyopharm Therapeutics share price volatility

Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $13.17 up to $28.04. A popular way to gauge a stock's volatility is its "beta".

KPTI.US volatility(beta: 0.63)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 0.6307. This would suggest that Karyopharm Therapeutics's shares are less volatile than average (for this exchange).

Karyopharm Therapeutics overview

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIOÂ), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site